A practical reference on lyophilized powder: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-12-19 and is reviewed periodically as new material appears.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Peptide fragment | Corresponds to hGH residues 176-191 |
| Common synonyms | AOD9604, hGH 176-191 | Also written as AOD-9604 |
| Typical form | Lyophilized powder | Often supplied in sealed vials |
| Solubility | Water-soluble | Dissolves in aqueous buffers |
| Regulatory status | Not approved as drug | Banned in sport; varies by country |
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
== VEGFR-2 == VEGFR-2 is a 210-230 kDa glycoprotein expressed in vascular endothelial cells and in hematopoietic stem cells and binds VEGF-A. VEGFR-2 is closely related to VEGFR-1 for they have common and specific ligands but VEGFR-2 is a highly active kinase while VEGFR1 is an impaired receptor tyrosine kinase. This receptor is a regulator in responses in the endothelial cells of VEGF. These regulations include permeability, proliferation, invasion and migration. The signaling pathways, Y1175 and Y1214, are the main autophosphorylation sites of the human VEGFR-2 followed by VEGF binding. Autophosphorylated VEGFR-2 is required for activation of several downstream pathways, which are hyperactivated in some tumors. These signaling pathways are important in tumor angiogenesis, which stimulates tumor growth by supplying the tumor with oxygen and nutrients. VEGFR-2 is overexpressed in several cancers, for example ovarian, thyroid, melanoma and medulloblastoma.
The Riken team then repeated the original 209Bi + 70Zn reaction and produced a second atom of 278113 in April 2005, with a decay chain that again terminated with the spontaneous fission of 262Db. The decay data were slightly different from those of the first chain: this could have been because an alpha particle escaped from the detector without depositing its full energy, or because some of the intermediate decay products were formed in metastable isomeric states. In 2006, a team at the Heavy Ion Research Facility in Lanzhou, China, investigated the 243Am + 26Mg reaction, producing four atoms of 266Bh. All four chains started with an alpha decay to 262Db; three chains ended there with spontaneous fission, as in the 278113 chains observed at Riken, while the remaining one continued via another alpha decay to 258Lr, as in the 266Bh chains observed at LBNL. In June 2006, the JINR–LLNL collaboration claimed to have synthesised a new isotope of element 113 directly by bombarding a neptunium-237 target with accelerated calcium-48 nuclei:
=== Controversy === Several Hardee's ad campaigns in the 2000s have been criticized by groups including Parents Television Council for their sexually suggestive nature. A campaign titled "More Than a Piece of Meat" featured scantily clad women appearing to receive sexual gratification from consuming Hardee's products, and "Name Our Holes" – an ad campaign and website promoting Hardee's Biscuit Holes. In January 2015, Carl's Jr. released a commercial online featuring model Charlotte McKinney advertising its new All Natural Burger to air regionally during Super Bowl XLIX. The ad features McKinney walking around a farmers' market, implying that she is "all natural" and uses double entendres to suggest that she is naked with strategically placed items in the market until it reveals McKinney in a bikini eating the All Natural Burger. Critics suggested that the ad "sets feminism back four decades," while others, including McKinney's elderly grandfather, enjoyed the ad. Until the YouTube video of the ad was privatized by Carl's Jr. in March 2017, it had over 13 million views and 10 thousand likes.
== Difference between channels and carriers == A carrier is not open simultaneously to both the extracellular and intracellular environments. Either its inner gate is closed, or its outer gate is closed. That is, its inner and outer gates are never open at the same time. In contrast, a channel can be open to both environments at the same time, allowing the molecules to diffuse without interruption. Carriers have binding sites, but pores and channels do not. When a channel is opened, millions of ions can pass through the membrane per second, but only 100 to 1000 molecules typically pass through a carrier molecule in the same time. Each carrier protein is designed to recognize only one substance or one group of very similar substances. Research has correlated defects in specific carrier proteins with specific diseases.
The binding of S-arrestin to rhodopsin is specific and involves changes that occur in rhodopsin after activation. Important serine (Ser) and threonine (Thr) residues in rhodopsin's tail, particularly Thr-340 and Ser-343, are phosphorylated by enzymes called GRKs. These phosphorylated residues strongly attract S-arrestin, helping it bind tightly and effectively shut down rhodopsin's signaling. Additionally, studies of the protein structure have shown that during activation, rhodopsin's transmembrane helix 7 (TM7) and helix 8 change shape. These changes expose a binding site that interacts with a specific part of arrestin called the "finger loop." This interaction, clearly seen in the crystal structure (PDB ID: 4ZWJ), shows how arrestin fits precisely onto activated and phosphorylated rhodopsin, efficiently stopping the visual signal. Arrestin at the U.S. National Library of Medicine Medical Subject Headings (MeSH)
Sources: en.wikipedia.org
Caesium-135 is a mildly radioactive isotope of caesium with a half-life of 1.33 million years. It decays via emission of a low-energy beta particle into the stable isotope barium-135. Caesium-135 is one of the seven long-lived fission products and the only alkaline one. In most types of nuclear reprocessing, it stays with the medium-lived fission products (including 137Cs which can only be separated from 135Cs via isotope separation) rather than with other long-lived fission products. As an exception, molten salt reactors create 135Cs as a completely separate stream outside the fuel (after the decay of bubble-separated 135Xe). The low decay energy, lack of gamma radiation, and long half-life of 135Cs make this isotope much less hazardous than 137Cs or 134Cs. Its precursor 135Xe has a high fission product yield (e.g., 6.3333% for 235U and thermal neutrons) but also has the highest known thermal neutron capture cross section of any nuclide. Because of this, much of the 135Xe produced in current thermal reactors (as much as >90% at steady-state full power) will be converted to practically stable 136Xe before it can decay to 135Cs despite the relatively short half-life of 135Xe. Little or no 135Xe will be destroyed by neutron capture after a reactor shutdown, or in a molten salt reactor that continuously removes xenon from its fuel, a fast neutron reactor, or a nuclear weapon.
== Clinical implications == The MEN1 phenotype is inherited via an autosomal-dominant pattern and is associated with neoplasms of the pituitary gland, the parathyroid gland, and the pancreas (the 3 "P"s). While these neoplasias are often benign (in contrast to tumours occurring in MEN2A), they are adenomas and, therefore, produce endocrine phenotypes. Pancreatic presentations of the MEN1 phenotype may manifest as Zollinger–Ellison syndrome. MEN1 pituitary tumours are adenomas of anterior cells, typically prolactinomas or growth hormone-secreting. Pancreatic tumours involve the islet cells, giving rise to gastrinomas or insulinomas. In rare cases, adrenal cortex tumours are also seen.
== Mechanism == PNGase F catalyzes the cleavage of an internal glycoside bond in an oligosaccharide. It cleaves all asparagine-linked complex, hybrid, or high mannose oligosaccharides unless the core GlcNAc contains an alpha 1,3- fucose. The asparagine residue, from which the glycan is removed, is deaminated to aspartic acid. PNGase F requires a minimum of two GlcNAc oligosaccharide residues attached to the asparagine in order for catalysis to occur. This enzyme utilizes a catalytic triad of cysteine-histidine-aspartate in its active site, which is a common motif for amidases. This motif contains a nucleophile, a proton donor, and a positive charge to stabilize the tetrahedral intermediate. The crystal structure of PNGase F from flavobacterium miningosepticum, with 1.8 Å resolution, was found to be folded in two domains, each with an eight-stranded antiparallel β barrel, or jelly roll, configuration. This structure is similar to lectins and glucanases, suggesting similarities with lectins and other carbohydrate-binding proteins.
== Further reading == Koli AK, Yearby C, Scott W, Donaldson KO (1969). "Purification and properties of three separate menadione reductases from hog liver". J. Biol. Chem. 244 (4): 621–9. doi:10.1016/S0021-9258(18)94400-5. PMID 4388793.
For services to 31 Squadron Royal Air Force Association. Henry Ashley Edwards, Consultant Anaesthetist, Ysbyty Gwynedd. For services to the Welsh Medical Committee. The Reverend John Gisborne Charteris Eldrid. For services to the Samaritans. Geoffrey Kenyon Elliott. For services to Forestry and to Wood Science. Robert William Elliott, Chairperson and Director, Wiltshire & Swindon Users' Network, and Chairperson, The Jumbulance Group. For services to disabled people in Wiltshire. David John Ellis, Grade 6, Ministry of Defence. Andrew James Erving, Grade 7, Foreign and Commonwealth Office. George Stanley Etchells, Member, Rotherham Metropolitan Borough Council. For services to Local Government. Eric Magnus Eunson, lately General Manager, Power System Development, National Grid Company plc. For services to the Electricity Industry. David Roger Evans. For services to Agriculture in Wales. Gwynne Howard Neill Evans, lately Grade 6, Department for Education and Employment. David Roger Evans. For services to Agriculture in Wales. John Ivan Ellis Farmer, Honorary Show Director, All England Jumping Course, Hickstead. For services to Show Jumping. William Harold Faulkner, Headteacher, Montrose Academy. For services to Education. David Alan Fawcett. For humanitarian services in the Caribbean. Ronald Paul Feeney, Governor 2, Her Majesty's Prison Stafford. Professor Christine Elizabeth Fell, Professor of Early English Studies, University of Nottingham. For services to Early English. John Ronald Fenner, Chairman, British Urban Regeneration Association.
Sources: en.wikipedia.org
Socialist Studies interprets the 1988 resolution as having completely changed the party's name and proscribing the use of the full form. They see this resolution as conflicting with the party's Declaration of Principles, one clause of which mentions the party's full name explicitly. It is largely on this basis that they justified their continued operation as the Socialist Party of Great Britain, claiming that they were expelled from the Socialist Party, not the Socialist Party of Great Britain. They also claim that they are entitled to use the name because the original Socialist Party of Great Britain no longer exists: The Socialist Party of Great Britain of 52 Clapham High Street, London SW4 7UN, is defunct and no longer exists as a political party. It does not produce political literature, hold propaganda meetings or contest elections. It cannot exist merely as a name without a body. [...] We are the only political organisation in this country bearing the title 'The Socialist Party of Great Britain'. More recently, the 1988 resolution was reversed at a conference in 2008.
The Jammu region, while less affected, also experienced a reduction in visitors during periods of heightened unrest. Episodes of violence and terror attacks have repeatedly disrupted the sector, leading to mass cancellations and long-term damage to the region's image as a safe destination. Notably, the 2019 advisory from the Government of India, following the abrogation of Article 370, resulted in the abrupt evacuation of tourists and a near-complete shutdown of the industry. Terror attacks such as the 2025 Pahalgam attack, which resulted in significant loss of life, have led to widespread cancellations, a sharp decline in bookings, and the closure of many tourist sites as part of security measures. The immediate aftermath of such incidents typically sees a steep drop in tourist arrivals, with ripple effects on employment and local businesses dependent on tourism. The sector’s recovery often takes several years, and recurring instability continues to act as a major constraint on its full potential. Despite these challenges, the region has demonstrated resilience, with tourism numbers rebounding during periods of relative calm. Periods of decrease in violence boosts tourism. In 2024, Jammu and Kashmir recorded over 23 million tourist visits. However, the volatility associated with insurgency is a persistent obstacle to sustainable tourism development.
== Related compounds == N-Methyliminodiacetic acid (MIDA), the N-methyl derivative of IDA Imidodiacetic acid, the amino diacetic acid N-(2-Carboxyethyl)iminodiacetic acid, a more biodegradable analogue of NTA N-hydroxyiminodiacetic acid (HIDA), HON(CH2CO2H)2 (registry number = 87339-38-6) See HIDA scan.
== German Empire (1871–1918) == The German Empire was born out of the North German Confederation as result of the Franco-Prussian War (1870/71). The Präsidium (the Prussian king), which now had also the title Emperor, named the chancellor. Political parties: None Centre
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.
No, it is a small fragment of the full growth hormone protein. It does not appear to stimulate growth or increase growth hormone levels in the same way. Its actions are thought to be more limited to metabolic pathways.
Regulatory status varies. It is not approved for medical use in the United States or many other countries. It is banned in sport by WADA, and its sale as a supplement or research chemical may be subject to legal restrictions.
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.